Edison Investment Research - Pixium Vision SA (ALPIX) Pixium Vision - Q3 results in line, awaiting pivotal study approval

Report

Edison Investment Research

Sean Conroy

Pixium Vision - Q3 results in line, awaiting pivotal study approval

Pixium Vision provided an update on its 9M20 cash flow results, which are broadly in line with H120 trends. The company reported a 9M20 operating cash outflow of €4.2m and a gross cash position of €13.3m at the end of the quarter. We believe Pixium’s funds on hand should be sufficient to support its ongoing operations into Q421, thus including at least several months of initial ramp-up of the upcoming PRIMAvera pivotal study on the Prima bionic vision system (BVS).

29/10/2020 5 EN

Underlying

Pixium Vision SA

Pixium Vision SA is a company that specializes in sensorial neuromodulation. Co. is also collaborating with scientific groups and clinicians at research institutes and clinical centers around the world, including Stanford University (USA). Co. is developing and aims to commercialize Bionic Vision Systems (BVS) – namely active implantable medical devices to treat blindness caused by degeneration of photoreceptor cells in the retina.

See profile

FR0011950641 Euronext Paris France

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

GlobeNewsWire

Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings

Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings Paris, France, February 2, 2024 – 02:00 p.m. (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, ...

February 2, 2024 February 2, 2024 1 EN

GlobeNewsWire

Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire

Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire Paris, France, 2ème février 2024 – 14h00 CET – Pixium Vision SA (Euronext Growth Paris – FR001400JX97 ; Mnemo : ALPIX), société de bioélectronique développant des systèmes de vision innovants pour permettre aux patients ayant perdu la vue de vivre de façon plus autonome, annonce la décision...

February 2, 2024 February 2, 2024 1 EN

GlobeNewsWire

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024 Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024 Paris, France, January 17, 2024 – 5:00 pm (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the Paris Commercial...

January 17, 2024 January 17, 2024 1 EN

AGBA - A transformational deal

On 18 April, AGBA announced a surprise deal to acquire 100% of Triller Corp, a global AI-driven social video platform, in an all-stock transaction. Triller is privately-owned but has been independently valued at US$3.2bn. AGBA’s management is using a US$4bn valuation for the combined entity, in which AGBA shareholders will own 20% and Triller shareholders 80%. Triller recorded FY23 revenues of US$45m on 450m user accounts and 2.2m creators but is loss-making. In FY23, AGBA reported revenues of US$54m and 400,000+ clients. The combined group expects synergies from expanding and marketing to Tri...

15h / 6m 15h / 6m 1 EN

Sean Conroy

Sean Conroy

Biodexa Pharmaceuticals - In a period of transition

FY23 was a transitional year for Biodexa, following the restructuring announced in March 2023 into a therapeutic company from a drug delivery specialist, and the implementation of cost-saving initiatives in light of the macroeconomic environment. The pipeline expansion primarily de-risks the business, partially fulfilled with the acquisition of lyn kinase activator tolimidone, for type 1 diabetes (T1D), in late 2023. Management estimates gross cash of £5.97m at end-FY23 to provide a runway into Q424, past the planned Phase IIa trial initiation for tolimidone. The next catalyst will likely be t...

19h / 16m 19h / 16m 1 EN

Toby Thorrington

Toby Thorrington

Norcros - Sale of Johnson Tiles UK agreed

Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well-covered dividend. We retain our estimates and value the shares at 246p, implying c 30% upside.

April 25, 2024 April 25, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Pixium Vision - Q3 results in line, awaiting pivotal study approval

Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings

Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024

AGBA - A transformational deal

Biodexa Pharmaceuticals - In a period of transition

Norcros - Sale of Johnson Tiles UK agreed

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe